Integra LifeSciences Holdings Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IART research report →
Range $13 – $25
Price Chart
About the company
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies.
- CEO
- Stuart Essig
- IPO
- 1995
- Employees
- 4,427
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on IART
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.03B
- P/E
- 80.75
- Fwd P/E
- 5.67
- PEG
- 0.12
- P/S
- 0.64
- P/B
- 1.00
- EV/EBITDA
- 12.00
- Div Yield
- 0.00%
- Gross Margin
- 52.46%
- Op Margin
- 38.30%
- Net Margin
- 0.79%
- ROE
- 1.24%
- ROIC
- 11.42%
Latest fiscal year · YoY change
- Revenue
- $1.64B+1.5%
- Gross Profit
- $845.23M-4.2%
- Op Income
- $68.32M
- Net Income
- $-516,474,000-7337.7%
- EPS
- $-6.73-7361.2%
- OCF Growth
- -61.1%
- FCF Growth
- -281.3%
- 52W High
- $20.49
- 52W Low
- $8.70
- 50D MA
- $14.13
- 200D MA
- $14.24
- Beta
- 1.28
- RSI (14)
- 45
- Avg Volume
- 1.04M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Integra LifeSciences posted third-quarter revenue at the low end of guidance, with strong neurosurgery and cash flow offset by Cincinnati flood disruption and weaker Tissue Reconstruction, and it cut full-year revenue expectations while reaffirming a path to recovery in 2027.· October 21, 2026
- Q3 revenue was $411.2 million, up 2.3% reported and 2.5% organic; adjusted EPS was $0.59 versus $0.54 a year ago.
- Specialty Surgery led the quarter with $304.1 million of revenue, up 3.9% reported and 4.2% organic, driven by neurosurgery strength.
- Tissue Reconstruction was $107.1 million, down 2.2% reported and organic, as growth in PriMatrix and DuraSorb was offset by continued pressure in UBM and slower-than-expected Integra Skin recovery.
- Cincinnati flooding reduced Q3 revenue by about $7 million, is expected to reduce Q4 revenue by another $15 million-$20 million, and is still expected to keep full manufacturing offline until Q2 2027.
- The company raised financial flexibility through $96 million of operating cash flow, $86 million of free cash flow, leverage of 3.8x, and a completed $2.1 billion refinancing.
Third-quarter revenue was $411.2 million, up 2.3% reported and 2.5% organic, at the low end of guidance. Adjusted EPS was $0.59 versus $0.54 in the prior-year period. Adjusted gross margin was 61.1% versus 62.9% a year ago; adjusted EBITDA was $80 million with a 19.4% margin versus 19.5% last year. Operating cash flow was $96 million, a record quarter, and free cash flow was $86 million, with adjusted free cash flow conversion of 185%. Specialty Surgery revenue was $304.1 million, up 3.9% reported and 4.2% organic; Tissue Reconstruction revenue was $107.1 million, down 2.2% reported and organic. For Q4, the company expects revenue of $413 million to $433 million. Full-year 2026 revenue guidance is $1.634 billion to $1.654 billion and adjusted EPS guidance is $2.30 to $2.40. Full-year adjusted gross margin is expected to be approximately flat versus 2025, which is 60 basis points below the prior expectation for 2026. Management said Cincinnati reduced Q3 revenue by approximately $7 million and is expected to reduce Q4 revenue by approximately $15 million-$20 million.
Stuart Essig said the quarter was disappointing mainly because the Cincinnati disruption was larger than expected and Tissue Reconstruction did not recover as anticipated, but he emphasized that neurosurgery strength, improved product availability, and the planned SurgiMend relaunch give the company a stronger base for growth. He framed 2026 as a year of meaningful operational progress, citing better supply, lower leverage, and a completed refinancing. His tone was candid but constructive, with repeated emphasis on execution, recovery, and a more consistent growth profile in 2027.
Lea Knight detailed the financial impact of the quarter and updated outlook, including $411.2 million of revenue, $0.59 adjusted EPS, 61.1% adjusted gross margin, $80 million of adjusted EBITDA, and $96 million of operating cash flow. She said gross margin pressure came mainly from Cincinnati lost gross profit and from product and portfolio mix, partially offset by cost reductions and productivity gains. She also highlighted $10 million of capex, $559 million of total liquidity, net debt of about $1.5 billion, leverage of 3.8x, and the $2.1 billion refinancing completed on October 19, noting an estimated $8 million of incremental interest expense in Q4 and $24 million more interest expense in 2027 versus the updated 2026 outlook.
Analysts pressed management on Tissue Reconstruction weakness, 2027 EPS growth potential, Cincinnati’s recovery path, and how much of the lost volume might come back. Management said Tissue Reconstruction’s base business is expected to stay flat in 2027, with growth contribution from SurgiMend, while also acknowledging ongoing pressure in UBM and slower share recapture in some Integra Skin SKUs. On Cincinnati, management said shipments should begin to resume in Q2 2027, but they would not assume meaningful back-order clearance and would model limited revenue contribution at first; they also said the lost volume is mostly tied to the Mayfield capital product and that some business will likely be lost to competitors, though they still expect to protect a significant share position.
The bullish case from the call is that core businesses outside Cincinnati are showing resilience, especially neurosurgery, where management sees strong momentum across several products and expects low- to mid-single-digit longer-term growth. Cash generation was strong, leverage came down, and the refinancing extended maturity and improved flexibility, while SurgiMend and DuraSorb offer a clearer growth path in breast reconstruction and hernia repair. Management also sounded confident that product availability has improved enough to shift more focus to commercial execution.
The main bear case is that Cincinnati disruption is still taking a meaningful toll, with revenue headwinds now extending into Q2 2027 and no meaningful back-order catch-up expected. Tissue Reconstruction is still uneven, with UBM and some Integra Skin SKUs under pressure from competition and slower share recapture, and management explicitly said the base business may be flat in 2027. EPS will also face a higher interest burden from the refinancing, plus continued tariff and Cincinnati gross profit pressure, even as some cost savings roll off.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.4%
- Shares Outstanding
- 77.80M
- Float Shares
- 58.64M
of shares held by institutions
213 13F filers
Buy/sell ratio 7.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for IART, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Josh GottheimerHouse · NJ05 | Sell | Jun 18, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Apr 5, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 16, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 13, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 16, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 20 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Jan 9, 19 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 10, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Feb 3, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Feb 10, 20 | Filing → |
| Thomas Roland TillisSenate · NC | Sell | Feb 13, 15 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 10.83M | ▲ 141.82K |
| Rubric Capital Management LP | 7.35M | ▼ 400.00K |
| Vanguard Group Inc | 7.21M | ▼ 168.50K |
| Invesco Ltd. | 4.16M | ▲ 415.00K |
| Vanguard Portfolio Management LLC | 3.94M | ▲ 196.68K |
| Morgan Stanley | 3.74M | ▲ 147.66K |
| Paradigm Capital Management Inc/Ny | 3.10M | ▼ 342.00K |
| State Street Corp | 3.02M | ▲ 72.96K |
| Vanguard Capital Management LLC | 2.92M | ▼ 21.91K |
| Dimensional Fund Advisors LP | 2.77M | ▲ 548.78K |
| Fuller & Thaler Asset Management, Inc. | 2.21M | ▼ 1.23M |
| Neuberger Berman Group LLC | 2.06M | ▼ 300.74K |
Held by 332 ETFs
Biggest fund positions in IART by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Caruso Andrea B | other | 0 |
| Oct 1, 26 | Caruso Andrea B | other | 0 |
| Oct 1, 26 | Caruso Andrea B | other | 0 |
| Oct 1, 26 | Caruso Andrea B | other | 0 |
| Oct 1, 26 | Caruso Andrea B | other | 0 |
| Oct 1, 26 | Caruso Andrea B | other | 0 |
| Oct 1, 26 | Caruso Andrea B | other | 0 |
| Sep 17, 26 | Shinn Lesha R | other | 0 |
| Sep 1, 26 | Veillon-Berteloot Chantal | other | 1,455 |
| Jul 1, 26 | Mosebrook Jeffrey | other | 937 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IART coverage
Recent articles, reports, and earnings notes.

Should You Buy the BioStem Technologies IPO? Here's the Setup
BioStem Technologies, Inc. (NASDAQ: BSEM) is expected to list on 2026-08-07, but the price range has not been disclosed. The company is coming to market through an expected Nasdaq uplisting rather than a traditional IPO prospectus. The bull case is a high-margin wound-care platform; the bear case is heavy customer concentration and a 2025 revenue drop.

Conexeu Sciences Inc. IPO: What to Know Before It Lists
Conexeu Sciences Inc. (NASDAQ: CNXU) is expected to list on 2026-05-21, with the price range not yet disclosed. The setup is a preclinical regenerative medicine story with no FDA-cleared product yet, so shareholders should watch for pricing, dilution, and how the market values the pipeline risk.
Want a deeper read on IART?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Integra (IART) Up 9.9% Since Last Earnings Report: Can It Continue?
zacks.com · Nov 20
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
prnewswire.com · Nov 19
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
globenewswire.com · Nov 17
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
globenewswire.com · Nov 10
Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference
globenewswire.com · Nov 6
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
prnewswire.com · Nov 5
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
globenewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.